Kidney-derived PCSK9-a new driver of hyperlipidemia in nephrotic syndrome?
Kidney Int
; 98(6): 1393-1395, 2020 12.
Article
em En
| MEDLINE
| ID: mdl-33276863
ABSTRACT
Increased plasma concentrations of proprotein convertase subtilisin/kexin type 9 or PCSK9, which reduces hepatic uptake of low-density lipoprotein by downregulation of the low-density lipoprotein receptor, have been reported in nephrotic patients and might contribute to hyperlipidemia in nephrotic syndrome. The results of the study by Molina-Jijon et al. found that renal PCSK9 expression was upregulated in the collecting duct of nephrotic patients and animals, suggesting that the kidney might be a major source for plasma PCSK9 in nephrotic syndrome.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Hipercolesterolemia
/
Hiperlipidemias
/
Síndrome Nefrótica
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article